Tarsus Pharmaceuticals (TARS) Net Cash Flow (2019 - 2026)

Tarsus Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$82.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 201.29% year-over-year to -$82.0 million; the TTM figure through Mar 2026 stood at -$74.2 million (down 382.95% YoY), while the FY2025 annual figure was $88.8 million, up 169.63% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$82.0 million, down from $70.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $119.9 million in Q3 2023, with the low at -$97.8 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$4.9 million (2024), against an average of -$3.9 million.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow tumbled 4469.8% in 2024, then surged 429.09% in 2025.
• Tarsus Pharmaceuticals' Net Cash Flow stood at -$97.8 million in 2022, then soared by 98.24% to -$1.7 million in 2023, then sank by 4469.8% to -$78.8 million in 2024, then jumped by 189.96% to $70.9 million in 2025, then plunged by 215.64% to -$82.0 million in 2026.
• Business Quant data shows TARS's Net Cash Flow at -$82.0 million in Q1 2026, $70.9 million in Q4 2025, and $16.1 million in Q3 2025.